SCHEMBL5568040

SCHEMBL5568040

Cc1ccc(Cl)cc1Nc1ncnc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.60
FADS1 O60427 1/20 0.60
LCK P06239 1/20 0.59
MAPK1 P28482 3/20 0.52
POLB P06746 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
HTT P42858 2/20 0.52
HIF1A Q16665 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
DAPK3 O43293 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
ERBB2 P04626 1/20 0.51
PIM1 P11309 1/20 0.51
PRKACA P17612 1/20 0.51
LTK P29376 1/20 0.51
MAPK8 P45983 1/20 0.51
CSNK1A1 P48729 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569110 0.89 EGFR (0.60) EGFRFADS1LCKMAPK1POLB
SCHEMBL9017038 0.86 EGFR (0.63) EGFRMAPK1POLBNPC1RAB9A
SCHEMBL5569117 0.85 HTT (0.61) EGFRMAPK1HTTMEN1KMT2A
SCHEMBL11082678 0.83 RXFP1 (0.63) EGFRFADS1LCKNPC1RAB9A
SCHEMBL8907064 0.83 EGFR (0.60) EGFRFADS1MAPK1NPC1HTT
SCHEMBL5568397 0.83 EGFR (0.68) EGFRFADS1LCKMAPK1POLB
SCHEMBL5564787 0.83 MEN1 (0.53) EGFRMEN1KMT2AAURKBPPARG
SCHEMBL5569119 0.82 TP53 (0.50) EGFRFADS1LCKPOLBMAPK14
Hydrochloric Acid SCHEMBL11093777 0.82 EGFR (0.59) EGFRFADS1LCKMAPK1NPC1
Hydrochloric Acid SCHEMBL11085544 0.82 RXFP1 (0.62) EGFRFADS1LCKHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885FADS1 4484/4885LCK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.